PTC Therapeutics, Inc. — 2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing, not a standalone fourth-quarter report. Amounts below are in U.S. dollars.
Business context
PTC is a global biopharmaceutical company focused on rare diseases. Its commercial portfolio included Translarna and Emflaza for Duchenne muscular dystrophy, Tegsedi and Waylivra in parts of Latin America and the Caribbean, and Evrysdi, commercialized by Roche under a collaboration. The company continued investing in gene therapy and other clinical-stage programs.
Financial results and liquidity
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Total revenue | $538.6 million | $380.8 million | Up 41% |
| Net product revenue | $428.9 million | $333.4 million | Up 29% |
| Collaboration revenue | $55.0 million | $42.6 million | Up 29% |
| Royalty revenue | $54.6 million | $4.8 million | Up $49.9 million |
| Research and development | $540.7 million | $477.6 million | Up 13% |
| Selling, general and administrative | $285.8 million | $245.2 million | Up 17% |
| Loss from operations | $(374.4) million | $(431.8) million | Loss narrowed |
| Net loss | $(523.9) million | $(438.2) million | Loss widened |
| Operating cash flow | $(251.3) million | $(194.1) million | Greater cash use |
- Translarna sales were $236.0 million, up 23%; Emflaza sales were $187.3 million, up 35%. Management attributed growth to new patients and prescriptions, continued compliance, geographic expansion, and improved access.
- Cash, cash equivalents and marketable securities totaled $773.4 million at year-end. Current assets were $954.4 million and current liabilities were $509.3 million.
- Debt included $150.0 million principal of 3.00% convertible notes due August 2022 and $287.5 million principal of 1.50% notes due September 2026. Separately, the liability for sold Evrysdi royalties was $734.0 million at year-end; it is classified as debt under the accounting described in the filing.
- Management said available resources and expected product cash flows should fund operations and capital expenditures for at least the next 12 months, while cautioning that this estimate depends on assumptions.
- The filing does not present a conventional consolidated gross-margin measure. Operating loss was about 69% of revenue and net loss about 97% of revenue, calculated from reported figures.
Material changes and notable items
- Revenue growth reflected both higher product sales and increased Evrysdi-related collaboration milestones and royalties. PTC received Roche milestones tied to Evrysdi’s EU and Japan launches and $500 million in worldwide annual sales.
- Operating expenses rose, including R&D investment in the pipeline and higher commercial and facility costs. Operating loss narrowed, but net loss increased, partly because 2020 included $85.2 million of other income while 2021 had $57.9 million of other expense.
- 2021 other expense included a $41.0 million unrealized foreign-exchange loss on an intercompany loan, plus unrealized losses on ClearPoint equity and debt investments.
- The company early adopted ASU 2020-06 for convertible-debt accounting. The adoption materially changed opening equity and debt balances; it did not represent a cash transaction.
Outlook, risks and contingencies
- Translarna: Its EEA authorization remains conditional, subject to annual renewal and Study 041. PTC expected the placebo-controlled results in mid-2022 and planned to submit results and available extension data by the end of Q3 2022. The FDA had previously issued a Complete Response Letter; Study 045 did not meet its prespecified primary endpoint. PTC said a U.S. NDA resubmission depended on a positive Study 041 outcome.
- Pipeline outlook: PTC expected an EMA opinion on PTC-AADC in April 2022 and anticipated submitting a U.S. BLA in Q2 2022. It expected 2022 results from trials of vatiquinone, PTC923 and emvododstat for COVID-19; vatiquinone results for Friedreich ataxia were expected in Q2 2023. These are management expectations, not guaranteed outcomes.
- Other milestones: PTC expected an ANVISA decision on Waylivra for familial partial lipodystrophy in the second half of 2022 and projected Phase 2/3 or Phase 2 starts for unesbulin in 2022.
- Funding commitments: PTC expected a $50 million Emflaza sales milestone payment in 2022 and stated it expected $70 million of Agilis-related payments upon achievement of specified PTC-AADC milestones. The 2022 convertible notes also mature in August 2022 unless converted, redeemed or repurchased.
- Principal risks: Failure to renew Translarna’s EEA authorization or meet Study 041 obligations; clinical-trial and regulatory uncertainty; gene-therapy manufacturing, administration and safety challenges; COVID-19-related enrollment, supply and regulatory disruptions; reimbursement and pricing pressure; competition; and reliance on external manufacturers and collaborators.
- Management reported no material legal proceedings. The financial statements received an unqualified audit opinion, and the auditor reported effective internal control over financial reporting.
Important facts for investors to verify
- Study 041 results, EMA renewal and any resulting changes to Translarna’s authorization, label or revenue outlook.
- Whether PTC-AADC meets regulatory requirements and proceeds on the stated EMA and FDA timelines, including manufacturing and delivery-system requirements.
- Cash use, available liquidity and funding for the August 2022 convertible-note maturity and expected contingent payments.
- Evrysdi sales, PTC’s retained royalty share after the royalty sale, and progress toward remaining Roche sales milestones.
- Product-level sales, payer access and reimbursement trends, particularly for Translarna and Emflaza.
- Progress and results for the 2022 pipeline readouts and trials, and whether COVID-19 or supply-chain issues affect execution.